Fluidigm Announces First Quarter 2020 Financial Results
May 07, 2020 16:05 ET
|
Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
March 17, 2020 08:03 ET
|
Cognition Therapeutics, Inc.
New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Fluidigm to Participate in Upcoming Investor Conferences
February 12, 2020 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Life Chiropractic College West uses biomarkers to support Vitalistic research
January 15, 2020 14:00 ET
|
Life Chiropractic College West
San Francisco Bay Area, California, Jan. 15, 2020 (GLOBE NEWSWIRE) -- How do we know – with irrefutable research and hard data – that someone who is living the chiropractic lifestyle is, in fact,...
Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting
October 10, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
July 09, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
MicroRNA (miRNA) Market To Reach USD 415.1 Million By 2026 | Reports And Data
May 20, 2019 13:05 ET
|
Reports And Data
Investments in the development of techniques & tools to overcome existing challenges in clinical translation of microRNA applications, strategic developments such as partnerships and mergers and...
Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
November 01, 2018 08:30 ET
|
Fluidigm Corporation
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sirona Dx,...
Global Biomarkers Market to Witness Double-Digit Growth to 2023
September 10, 2018 05:00 ET
|
BCC Research
WELLESLEY, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Major drivers for growth of the global biomarkers market include a rise in government grants and research funding, the high prevalence of cancer...
Fluidigm Announces Second Quarter 2018 Financial Results
August 02, 2018 16:05 ET
|
Fluidigm Corporation
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE...